Alaunos Therapeutics (TCRT) Other Non-Current Liabilities (2009 - 2023)
Alaunos Therapeutics (TCRT) reported Other Non-Current Liabilities of $28000.0 for Q1 2023, little changed quarter-over-quarter from $28000.0 in Q4 2022.
Alaunos Therapeutics (TCRT) Other Non-Current Liabilities (2009 - 2023) Analysis & Trends
Alaunos Therapeutics has reported Other Non-Current Liabilities for 12 years, with the latest figure at $28000.0 in Q1 2023.
- For the quarter ending Q1 2023, Other Non-Current Liabilities changed N/A year-over-year to $28000.0; the trailing twelve-month figure through Mar 2023 stood at $28000.0 (changed N/A YoY), and the FY2022 full-year result was $28000.0, changed N/A from the prior year.
- Other Non-Current Liabilities for Q1 2023 stood at $28000.0, roughly flat from $28000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $28000.0 in Q2 2022, with the low at $28000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Alaunos Therapeutics | 4.31 Mn | 3.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 28,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 28,000.00 |
| Jun 30, 2022 | 28,000.00 |
| Sep 30, 2018 | 2.60 Mn |
| Jun 30, 2018 | 2.36 Mn |
| Mar 31, 2018 | 2.47 Mn |
| Dec 31, 2017 | 2.42 Mn |
| Sep 30, 2017 | 2.35 Mn |
| Jun 30, 2017 | 2.48 Mn |
| Mar 31, 2017 | 2.47 Mn |
| Dec 31, 2016 | 862,000.00 |
| Sep 30, 2016 | 694,000.00 |
| Jun 30, 2016 | 694,000.00 |
| Jun 30, 2015 | 17,000.00 |
| Sep 30, 2014 | 20,000.00 |
| Jun 30, 2014 | 20,000.00 |
| Mar 31, 2014 | 20,000.00 |
| Dec 31, 2013 | 20,000.00 |
| Sep 30, 2013 | 20,000.00 |